ImmunityBio, Inc. (IBRX) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Preliminary Net Product Revenue | 44.18M | FY2026-Q1 |
| ANKTIVA Unit Sales Volume Growth | 168.00 percent | FY2026-Q1 |
| Unit Sales Volume Growth Quarter-Over-Quarter | 168.00 percent | FY2026-Q1 |
| Net Product Revenue Quarter-Over-Quarter Increase | 20.00 percent | FY2025-Q4 |
Back to IBRX overview · IBRX earnings · IBRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.